AbbVie Reports Second-Quarter 2024 Financial Results
...response (DOR), a key secondary endpoint, of 8.25 months. The safety profile of Elahere was consistent with findings from previous studies, and no new safety concerns were identified. Full data from the PICCOLO study will be presented at a future medical...
Zur Pressemeldung auf news.abbvie.com